NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Empaglifozin in Early Diabetic Kidney Disease

Phase 3

Withdrawn

Conditions: Diabetic Kidney Disease
Diabetes Mellitus Type 2

Interventions: Other: Placebo
Drug: Empagliflozin

First Posted Date: 2017-06-02

Last Posted Date: 2020-02-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registration Number: NCT03173963

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Phase 2

Terminated

Conditions: Pheochromocytoma
Paraganglioma
Gastrointestinal Stromal Tumors
Carcinoma, Renal Cell
Renal Neoplasms

Interventions: Drug: SGI-110 (guadecitabine)

First Posted Date: 2017-05-24

Last Posted Date: 2022-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 9

Registration Number: NCT03165721

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Juvenile Xanthogranuloma
Langerhans Cell Histiocytosis
Malignant Glioma
Recurrent Childhood Rhabdomyosarcoma
Recurrent Ewing Sarcoma
Recurrent Osteosarcoma
Recurrent Primary Central Nervous System Neoplasm
Refractory Hepatoblastoma
Refractory Medulloblastoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Other: Laboratory Biomarker Analysis
Procedure: Bone Marrow Aspiration and Biopsy
Procedure: Mutation Carrier Screening
Procedure: Bone Scan
Drug: Larotrectinib Sulfate
Procedure: Computed Tomography
Drug: Olaparib
Drug: Palbociclib
Drug: Tazemetostat
Drug: Samotolisib
Drug: Selumetinib Sulfate
Drug: Ensartinib
Drug: Vemurafenib
Drug: Ulixertinib
Drug: Tipifarnib
Drug: Erdafitinib
Procedure: Magnetic Resonance Imaging
Other: Pharmacological Study
Drug: Selpercatinib
Procedure: Radionuclide Imaging
Procedure: Positron Emission Tomography
Procedure: X-Ray Imaging

First Posted Date: 2017-05-16

Last Posted Date: 2025-05-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1376

Registration Number: NCT03155620

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 169 locations

Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Unresectable Epithelioid Hemangioendothelioma
Locally Advanced Epithelioid Hemangioendothelioma
Metastatic Epithelioid Hemangioendothelioma

Interventions: Other: Questionnaire Administration
Drug: Trametinib

First Posted Date: 2017-05-10

Last Posted Date: 2024-11-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT03148275

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States

and more 33 locations

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Phase 2

Active, not recruiting

Conditions: Unresectable Alveolar Soft Part Sarcoma
Metastatic Alveolar Soft Part Sarcoma

Interventions: Drug: Atezolizumab
Procedure: Biospecimen Collection
Biological: Bevacizumab
Procedure: Computed Tomography

First Posted Date: 2017-05-05

Last Posted Date: 2025-04-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 63

Registration Number: NCT03141684

Locations: 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 39 locations

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Phase 1

Active, not recruiting

Conditions: Pleural Malignant Mesothelioma

Interventions: Biological: Anetumab Ravtansine
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Other: Pharmacological Study

First Posted Date: 2017-04-24

Last Posted Date: 2024-10-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT03126630

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States

and more 30 locations

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Phase 2

Completed

Conditions: Liver Cancer
Biliary Tract Neoplasms
Cholangiocarcinoma
Bile Duct Cancer
Gallbladder Cancer

Interventions: Biological: Pembrolizumab (MK-3475)
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2017-04-13

Last Posted Date: 2021-12-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT03111732

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010

Completed

Conditions: Viral Infections

First Posted Date: 2017-04-13

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 730

Registration Number: NCT03111745

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Phase 2

Withdrawn

Conditions: Neoplasms, Nerve Tissue
Neurofibromatosis 1
Heredodegenerative Disorders, Nervous System
Peripheral Nervous System Diseases

Interventions: Drug: Selumetinib (AZD6244 hyd sulfate) 50mg/dose
Drug: Selumetinib (AZD6244 hyd sulfate) 25mg/m2

First Posted Date: 2017-04-12

Last Posted Date: 2019-04-05

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT03109301

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Glioblastoma
Gliosarcoma
MGMT-Unmethylated Glioblastoma
Glioblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Magnetic Resonance Imaging
Drug: Navtemadlin
Radiation: Radiation Therapy

First Posted Date: 2017-04-11

Last Posted Date: 2025-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT03107780

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States

and more 8 locations

Home Terms & Conditions Privacy Policy